Related Experiment Video
Updated: May 4, 2026
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Standards for fecal microbiota transplant: Tools and therapeutic advances
Ilia Belotserkovsky1, Lisa M Stabryla2, Monique Hunter2
1BIOSTER Technological Research Institute, Lyon, France.
Abstract:
Fecal microbiota transplantation (FMT) has been demonstrated to be efficacious in preventing recurrent Clostridioides difficile (C. difficile) infections, and is being investigated for treatment of several other diseases including inflammatory bowel disease, cancer, obesity, liver disease, and diabetes. To speed up the translation of FMT into clinical practice as a safe and standardized therapeutic intervention, additional evidence-based technical and regulatory guidance is needed. To this end in May of 2022, the International Alliance for Biological Standardization (IABS) and the BIOASTER Microbiology Technology Institute hosted a second webinar to discuss key issues still impeding the advancement and standardization of FMT. The goal of this two-day webinar was to provide a forum for scientific experts to share and discuss data and key challenges with one another. Discussion included a focus on the evaluation of safety, efficacy, clinical trial design, reproducibility and accuracy in obtained microbiome measurements and data reporting, and the potential for standardization across these areas. It also focused on increasing the application potential and visibility of FMT beyond treating C. difficile infections.
Insights
Fecal microbiota transplantation (FMT) shows promise beyond C. difficile infections. Experts convened to discuss standardizing FMT safety, efficacy, and trial design for broader therapeutic applications.
Area of Science:
- Microbiology
- Gastroenterology
- Immunology
Background:
- Fecal microbiota transplantation (FMT) is effective for recurrent Clostridioides difficile infections.
- FMT is being explored for inflammatory bowel disease, cancer, obesity, liver disease, and diabetes.
- Standardization and regulatory guidance are crucial for advancing FMT in clinical practice.
Purpose of the Study:
- To discuss key challenges impeding the advancement and standardization of FMT.
- To foster collaboration among scientific experts for FMT development.
- To explore FMT's potential beyond C. difficile infections.
Main Methods:
- A webinar hosted by IABS and BIOASTER in May 2022.
- Expert discussions on safety, efficacy, clinical trial design, and data reporting.
- Focus on reproducibility and accuracy in microbiome measurements.
Main Results:
- Identified critical areas for FMT standardization: safety, efficacy, trial design, and data accuracy.
- Highlighted the need for evidence-based technical and regulatory guidance.
- Emphasized increasing FMT application potential and visibility.
Conclusions:
- Standardization of FMT is essential for its safe and effective translation into broader clinical use.
- Further research and regulatory frameworks are needed to support FMT development.
- FMT holds significant therapeutic potential for various diseases beyond C. difficile infections.
